Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15300.203 | 0.0129 | -0.9884 | 0.8443 | |
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 13.3 | uM | 15300.203 | 0.0129 | -0.9884 | 0.8443 | |
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15300.203 | 0.0113 | -0.9901 | 0.8443 | |
| HCC1187 | TNBC | Basal A | Bortezomib | Proteasome | Proteasome | 66.7 | uM | 15300.203 | 0.0113 | -0.9901 | 0.8443 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7435.074 | 1.0394 | 1.0921 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7435.074 | 1.0394 | 1.0921 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7435.074 | 0.9171 | 0.8081 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7435.074 | 0.9171 | 0.8081 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7435.074 | 0.9512 | 0.8866 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7435.074 | 0.9512 | 0.8866 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7435.074 | 0.5102 | -0.0872 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7435.074 | 0.5102 | -0.0872 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7435.074 | 0.1088 | -0.8493 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7435.074 | 0.1088 | -0.8493 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7435.074 | 0.0693 | -0.9110 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7435.074 | 0.0693 | -0.9110 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7435.074 | 0.0553 | -0.9315 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7435.074 | 0.0553 | -0.9315 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7435.074 | 0.0786 | -0.8969 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7435.074 | 0.0786 | -0.8969 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7435.074 | 0.1004 | -0.8629 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 167 | uM | 7435.074 | 0.1004 | -0.8629 | 0.8579 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7436.074 | 0.9625 | 0.9382 | 1.2173 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7436.074 | 0.9625 | 0.9382 | 1.2173 | |
| HCC1395 | TNBC | Basal B | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7436.074 | 0.9577 | 0.9302 | 1.2173 |